Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck KGaA
Biotech
Merck KGaA pledges $50M to new biotech with eye to acquisition
The cash will power Saturnus Bio's research into genetic heart diseases, with Merck KGaA holding the exclusive right to buy the NewCo down the line.
Darren Incorvaia
Jun 23, 2026 10:16am
Perrigo CEO ousted over ‘personal conduct’—Chutes & Ladders
Jun 12, 2026 8:30am
Merck KGaA, Remepy team up on hybrid drugs for rare tumors
Apr 28, 2026 7:00am
Storm secures $56M series C, launches ph. 2 sarcoma trial
Apr 16, 2026 10:12am
'Can it deliver?': Why Big Pharma has entered the quantum realm
Apr 10, 2026 7:20am
Merck KGaA drops pipeline asset from SpringWorks buyout
Mar 5, 2026 4:33pm
